A trial looking at a different way of giving posaconazole to prevent fungal infection after treatment for some blood cancers
Cancer type:
Status:
Phase:
This trial looked at giving posaconazole in a different way to prevent fungal infection after treatment for acute myeloid leukaemia (AML), myelodysplastic syndrome (MDS) and chronic myeloid leukaemia (CML).
More about this trial
Doctors can treat AML, MDS and CML with chemotherapy or a bone marrow or stem cell transplant. One of the side effects of both these treatments is a drop in white blood cells causing an increased risk of infection, including fungal infection.
Posaconazole is a drug that doctors use to treat or prevent fungal infection. It is a liquid that you swallow. The researchers developed another form of posaconazole that you have as a 
. The researchers wanted to measure the level of posaconazole in the blood after having it through a drip. They did this by taking blood samples.
The aims of this trial were to find out the
- Levels of posaconazole in the blood before and after having it through a drip
- Side effects of having posaconazole through a drip
- Levels of posaconazole in the blood after switching from having it as a drip to a liquid that is swallowed
Summary of results
Despite attempting to contact the trial team, we have not been able to have the results for this trial checked.
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Dr Samir Agrawal
Supported by
Merck, Sharp & Dohme
Schering Plough Research Institute
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
